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Abstract
Background: Physical activity (PA) is associated with reduced hospitalisations and maintenance of lung function in
patients with Cystic Fibrosis (CF). PA is therefore recommended as part of standard care. Despite this, there is no
consensus for monitoring of PA and little is known about perceptions of PA monitoring among children and young
people with CF. Therefore, the research aimed to explore patients’ perceptions of PA and the acceptability of using
PA monitoring devices with children and young people with CF.
Methods: An action research approach was utilised, whereby findings from earlier research phases informed
subsequent phases. Four phases were utilised, including patient interviews, PA monitoring, follow-up patient
interviews and health care professional (HCP) interviews. Subsequently, an expert panel discussed the study to
develop recommendations for practice and future research.
Results: Findings suggest that experiences of PA in children and young people with CF are largely comparable to
their non-CF peers, with individuals engaging in a variety of activities. CF was not perceived as a barrier per
se, although participants acknowledged that they could be limited by their symptoms. Maintenance of health
emerged as a key facilitator, in some cases PA offered patients the opportunity to ‘normalise’ their condition.
Participants reported enjoying wearing the monitoring devices and had good compliance. Wrist-worn devices
and devices providing feedback were preferred. HCPs recognised the potential benefits of the devices in
clinical practice.
Recommendations based on these findings are that interventions to promote PA in children and young people with
CF should be individualised and involve families to promote PA as part of an active lifestyle. Patients should receive
support alongside the PA data obtained from monitoring devices.
Conclusions: PA monitoring devices appear to be an acceptable method for objective assessment of PA among
children and young people with CF and their clinicians. Wrist-worn devices, which are unobtrusive and can display
feedback, were perceived as most acceptable. By understanding the factors impacting PA, CF health professionals will
be better placed to support patients and improve health outcomes.
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Background
Cystic Fibrosis (CF) affects approximately 11,000 individ-
uals in the United Kingdom (UK), with median predicted
survival reported as 45 years of age [1]. CF is an autosomal
recessive disorder caused by mutation of the CF Trans-
membrane Conductance Regulator (CFTR) gene. The
CFTR protein has an important role in co-ordinating
transepithelial salt transport, which impacts on a number
of important physiological functions [2]. Most import-
antly, the salt transport defect impairs mucociliary airway
clearance by disrupting the airway surface liquid and pre-
disposing the airway to a build-up of excess and viscous
mucus. Subsequent chronic airway infection and inflam-
mation lead to airway damage and eventual respiratory
failure as the primary cause of early death [1]. In addition,
the CF defect impacts on other epithelial surfaces, such as
the sweat gland, pancreas and liver [3].
CF is also characterised by reduced exercise capacity
[4] and, although the exact mechanisms are not yet fully
understood, physical inactivity, pulmonary, cardiac, and
peripheral skeletal muscle function all contribute [5].
Critically, higher aerobic fitness is associated with re-
duced mortality in patients with CF and therefore pro-
vides useful prognostic information [4]. Furthermore,
physical activity (PA) is related to aerobic fitness, inde-
pendent of sex, lung function, body size and muscle
power [6], with higher PA associated with a slower de-
cline in lung function [7] and fewer hospitalisations [8].
There is good evidence that PA has a positive impact on
bone mineral density [9], glycaemic control [10] and
mucociliary clearance [11], all of which contribute to
wellbeing for a person with CF.
PA promotion and exercise prescription are currently
recommended as part of standard CF care, alongside
chest physiotherapy [12]. Despite the documented bene-
fits and clinical recommendations there is some evi-
dence to suggest that children with CF engage in less
strenuous PA than age-matched controls [13]. The re-
duction in PA has been attributed to a number of per-
ceived barriers including progressive lung function
decline, symptoms of breathlessness, coughing and fa-
tigue [14] as well as the burdensome treatment regimen
associated with CF [15]. High treatment burden may in-
fluence the acceptability of additional measures such as
PA monitoring. Additionally, patients with CF are ex-
perts in their condition and are typically very engaged in
their medical care and self-care. They would need to
value PA monitoring to make PA assessment feasible.
In order to provide guidance on PA, clinicians require
knowledge of population specific barriers and facilitators
for PA as perceived by children and young people with
CF. Despite PA assessment and advice being perceived
as important by clinicians, PA assessment is not com-
mon or consistent in CF centres [16]. Moreover, there is
no consensus for monitoring or reporting of PA in CF
[16]. There is little known about perceptions and accept-
ability of PA monitoring among children and young
people with CF. Previous research has highlighted the
need to better understand self-efficacy for PA and suggests
that self-monitoring is central to all PA behaviours [17].
Though this research does not specifically refer to
self-monitoring via monitoring devices it is possible that
PA monitoring devices may feed into this self-monitoring
process. Accordingly, exploring clinicians’ knowledge and
perceptions of PA monitoring as well as those of the pa-
tients is needed to move towards the utilisation of PA
monitoring devices as part of routine clinical care.
Methods
Ethical considerations
Ethical approval was sought and granted by South West
Cornwall and Plymouth National Health Service (NHS)
Research Ethics Committee and Liverpool John Moores
University Ethics Committee prior to data collection.
NHS Caldicott principles were strictly adhered to
throughout, all data were anonymised and all personal
details kept confidential. Parents/carers written consent
and participants’ written assent were obtained. Parents/
carers were also invited to be present during their child’s
interviews.
The Medicines for Children Research Network Clinical
Trials Network (MCRN) consultative group situated at
Alder Hey Children’s NHS Foundation Trust, were con-
sulted to appraise the ‘appropriateness’ of the language
used in the study participant information sheets, consent
forms and interview schedule. To ensure face validity,
the interview schedule was reviewed during develop-
ment, prior to phase one commencement.
Aims
The overarching aim of the research was to explore the
use of PA monitoring devices with children and young
people with CF. As part of this, our objectives were to: (1)
explore barriers, facilitators and perceptions of PA among
children and young people with CF; (2) explore the ac-
ceptability of a range of PA monitoring devices; (3) ex-
plore clinicians’ existing knowledge and perceptions of PA
monitoring, and; (4) explore the clinical application of PA
monitoring as part of routine clinical care as well as iden-
tifying any disease specific limitations to PA monitoring.
Design
An action research approach was utilised to achieve the
study objectives whereby an iterative approach was used
with findings from earlier research phases informing
subsequent phases, of which there were four in total (see
Additional file 1). The first included patient interviews
to explore perceptions of PA. The second phase included
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the allocation of PA monitoring devices. Phase three had
two components which ran simultaneously. The first in-
cluded follow-up patient interviews informed by phases
one and two. The second included health care profes-
sional interviews. Phase four included an adapted con-
sensus approach, involving an expert panel to discuss
the study findings, to develop recommendations and to
inform future research directions. A researcher trained
in qualitative research methods (CH) conducted all in-
terviews and subsequent analysis.
Participants
Participants were recruited from the CF clinic at Alder
Hey Children’s Hospital. Potential participants were
identified by members of the usual care team from the
clinic database. Inclusion criteria included participants
aged between 8 and 16 years, with a confirmed diagnosis
of CF. Initially, potential participants were approached
during their routine clinical appointments by a member
of their CF care team, who briefly explained the purpose
of the study. Parents/carers of children and young
people who expressed an informal interest were later
formally invited to participate in the study by a re-
searcher via telephone. From 13 potential participants
initially identified, 9 formally agreed to participate (5 fe-
male; mean age 12 ± 3 years). The remaining 4 either
verbalised they were no longer willing to participate or
the researcher was unable contact their parents/carers.
Procedure
Phase 1
An open-ended, semi-structured interview protocol was
devised using the principal enabling, reinforcing and
predisposing factors of the Youth Physical Activity Pro-
motion Model (YPAPM) [18]. The YPAPM is consistent
with the socio-ecological model of health promotion and
describes the hypothesised influences of diverse corre-
lates on children’s and young people’s PA participation.
Use of the YPAPM facilitated the development of a
theory-driven interview schedule that would elicit beliefs
and attitudes towards PA and reveal psychological en-
ablers and barriers of PA as perceived by each individual,
whilst allowing the researcher to explore individual nu-
ances relating to the experience of PA in children and
young people with CF.
Semi-structured interviews were conducted between
children and young people with CF and the researcher
(CH). It was felt that parent/carer presence would be re-
assuring for the participants, creating a positive and
comfortable interview environment. In the interest of in-
clusivity some interview questions were directed specif-
ically towards the parent/carer, however these questions
were separated before analysis. Parents/carers were also
asked, where appropriate, to prompt their child only to
expand upon examples given when explaining their ex-
periences of PA and not to respond directly for them.
Interviews were arranged to take place at a time and
place most convenient to the participants parents/carers,
the majority were in the participants own home, with
one at Alder Hey Children’s NHS Foundation Trust
Hospital.
Data analysis Participants were assigned a participant
number (P1–P9) to protect participant confidentiality.
Data analysis utilised a broad model of interpretative
phenomenology as described by Fereday et al. [19]. Iden-
tification of emerging themes at the manifest level were
discussed and coded between two researchers (CH &
ZK) following each interview. Resultant themes were
further discussed with reference to the interview data
until final themes were determined and clustered around
the YPAPM. As a result, no new themes were identified
following interview with P9. Transcripts were deduct-
ively and inductively coded, illustrative quotes were ex-
tracted and clustered around emergent themes anchored
according to the main factors of the YPAPM.
Phase 2
Phase 2 commenced midway through phase 1 and the
two phases ran concurrently until the final participant
interview was completed.
Each of the 9 participants were allocated PA monitor-
ing devices to assess their acceptability in children and
young people with CF. Allocation ensured that each par-
ticipant received a research grade device alongside a
consumer level device. Participants wore either a GEN-
EActiv (ActivInsights Ltd., Cambs, UK) or ActiGraph
GT3X+ (ActiGraph, Pensacola, FL) triaxial accelerom-
eter on the non-dominant wrist or left hip, respectively.
Both devices have demonstrated acceptable validity and
reliability for use with children and young people [20].
In addition to the accelerometers participants were allo-
cated either a Yamax Digiwalker pedometer (Yamax UK
and Europe, Tasley UK) or one of two consumer level
PA trackers; ‘Fitbit Flex’ or ‘Moves’ smartphone applica-
tion (Table 2). Unfortunately, only one participant was
able to trial the ‘Moves’ application, as it required partic-
ipants to have a compatible smartphone. Participants
were asked to wear the devices for seven consecutive
days and were provided with instructions for how to
wear the devices as well as an information sheet. Partici-
pants were asked to wear the devices during waking
hours, unless engaging in water-based activity. Partici-
pants were instructed to clip the pedometer onto the
waistband of their clothing or to wear the Fitbit on their
wrist like a watch. The participant using the ‘Moves’ ap-
plication was informed that the application is always
running and that they should keep their phone on their
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possession throughout the day and to use it as usual.
Additionally, participants allocated a Fitbit device were
shown how to access the Fitbit dashboard, although
were not given specific instructions about how to use
the available features, as the researchers did not want to
influence how participants explored such features.
After trialling each device participants were asked to
complete a short questionnaire to obtain a self-reported
measure of satisfaction of using the devices (see Add-
itional file 2). This comprised of 10 statements, which
required participants to rate their response along a
5-point Likert scale. The ‘Moves’ application question-
naire only comprised of 9 of the relevant statements and
Likert scales, excluding a question relating to the com-
fort of wearing a device. The questionnaire served to
provide preliminary information to inform subsequent
interviews.
Data analysis Both the GENEActiv and ActiGraph tri-
axial accelerometers were initialised to record data at a
frequency of 100 Hz using GENEActiv PC software (ver-
sion 2.2, Activinsights, Cambs, UK) and ActiLife soft-
ware (version 6.11.0, ActiGraph corp, Pensacola, FL)
respectively. The raw ActiGraph and GENEActiv data
files were processed in R (http://cran.r-project.org) using
the GGIR package (version 1.5–7) which autocalibrated
the raw triaxial accelerometer signals [21]. Accelerom-
eter wear time inclusion criteria were a minimum of
600 min∙day− 1 for at least any 3 days [22]. Non-wear
was estimated on the basis of the standard deviation and
value range of each accelerometer axis, calculated for
moving windows of 60 min with 15 min increments
[23], which has been applied previously in studies in-
volving children [24]. For each 15 min period detected
as non-wear time over the valid days, missing data were
replaced by the mean value calculated from measure-
ment on other days at the same time of day [21].
The self-report questionnaires were analysed to assess
compliance with the remaining devices and to inform
Phase 3. The questionnaire also provided information
relating to the experience of wearing each device, which
were explored further in phase 3.
Phase 3
Following the action research approach, phase 1 and 2
findings were formative to the methodology used during
phase 3. Phase 3 consisted of patient follow-up inter-
views and health care professional (HCP) interviews.
Participant interviews The remaining participants were
invited to participate in the follow-up semi-structured
interviews with the PA data collected in phase 2 re-
ported back to patients as part of the interview. Inter-
view questions focussed upon the experiences and
opinions of each participant’s acceptability of the PA de-
vices allocated during phase 2. Individualised interview
schedules were designed for each participant, informed
by participant’s individual responses to the phase 2 feed-
back questionnaires, and also their activity and sedentary
levels as measured by their allocated accelerometry
device. In addition, related themes of acceptability
pertaining to the influence of others (family and
peers) and change in PA (attitudes and behaviours)
were explored.
Health care professional interviews During phase 1
participants identified the Clinical Lead Consultant for CF
(HCP-C), a Dietitian with special interest in CF (HCP-D)
and a Specialist Physiotherapist in CF (HCP-P) as key
members of the multi-disciplinary CF team. Therefore,
during phase 3, three one-to-one semi-structured inter-
views were conducted to explore the clinicians’ percep-
tions of PA monitoring in children and young people with
CF. The semi-structured interview schedule consisted of
15 open-ended questions to explore opinions, existing
knowledge and experience of using PA monitoring de-
vices, including, the perceived benefits and barriers of
using PA monitoring devices and acceptability of using PA
monitoring devices as part of routine clinical practice (see
Additional file 3). In addition to the HCP interviews, an
online survey was disseminated to Physiotherapists across
the UK, via regional CF representatives. The survey con-
sisted of 5 questions designed to explore issues concerning
the promotion of PA and the feasibility of using PA moni-
toring in clinical practice. The results of which converged
with data from the HCP interviews and are therefore dis-
cussed together throughout.
Phase 4
A single round consensus technique was used to exam-
ine the findings of previous phases, to develop
evidence-based recommendations and to direct future
research. To reflect on the findings in the context of a
real-world clinical setting participation of the HCPs was
essential. However, due to their clinical duties, it was not
feasible to follow the iterative process representative of
the Delphi consensus technique in its entirety, hence the
single round technique was adopted. An expert focus
group was developed, consisting of five expert-members
including HCPs and researchers. The Clinical Lead Con-
sultant and Specialist Physiotherapist in CF who partici-
pated in the earlier phases of the research participated in
the focus group, unfortunately the Dietitian was unable
to accept the invitation to participate in the focus group
due to clinical commitments. Two researchers from
within the PA field also participated in the focus group,
one with expertise in PA monitoring and exercise pre-
scription in children and a second with expertise as a
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Sports and Exercise Psychologist. The focus group was
facilitated by an additional researcher (CH). In total,
5-expert-members attended the meeting, which was re-
corded using a Dictaphone and transcribed verbatim
(Additional file 4).
Members were provided with a working document
(see Additional file 5) in advance of the focus-group
meeting. The document outlined the session structure
and summarised the key findings from phases 1–3.
Members independently reviewed the summary to for-
mulate their own opinions concerning PA monitoring
among children and young people with CF ahead of the
meeting.
Principles of the nominal consensus technique were
applied to develop a structured session for the expert-
members panel (see Additional file 6). Drawing upon
their respective expertise, each member was invited to
present 2 or 3 relevant questions and/or statements
which they perceived to be priority issues in the use of
PA monitoring among children and young people with
CF. Once each member had explicitly stated their ideas,
a discussion between panel members was initiated to ex-
plore and expand upon the issues identified. Equal atten-
tion was given to areas of consensus and non-consensus,
areas of agreement and non-agreement were each dis-
cussed. Priority issues were noted and organised into
themes. Panel members also independently ranked
each issue, according to their perceived priority
significance within the relevant theme and collect-
ively. This was completed after the meeting via email,
which allowed members privacy to reflect upon and
consider the key priorities and discussion points (see
Additional file 7). This was returned to the facilitator
who organised the emerging issues (Table 3).Qualitative
data are reported following the consolidated criteria for
reporting qualitative research (COREQ) checklist (see
Additional file 8).
Results
Phase 1
Nine interviews were conducted, recorded using a Dicta-
phone and transcribed verbatim. Interviews lasted be-
tween 39 and 94 min (mean = 61.5 min), generating 247
pages (Arial font, size 12 double spaced) and 554 min of
audio data. Barriers and facilitators to PA are outlined in
(Table 1). Individuals with CF engage in a variety of ac-
tivities and enjoy PA. Maintenance of health and im-
proved fitness emerged as a key facilitator of PA, with
participants recognising the prospective long-term bene-
fits of PA. Participants acknowledged the reinforcing in-
fluence that parents/carers, peers and coaches have on
PA engagement, in promoting family cohesiveness and
normalising the condition. Further to this, the CF
Physiotherapist was highlighted as being the most influ-
ential member of the CF team in reinforcing PA
engagement.
Table 1 Illustrative quotes exploring PA perceptions among children and young people with CF
Physical activity
participation
Enabling factors Perceived barrier Perceived enabler
Limited PA facilities available locally Community activities facilitated by private
clubs (Thai boxing, football, dance, table
tennis, gymnastics) and/or local authorities.
“A few more different clubs that do different
sports that are around, because there isn’t
many.” (P4, pg7, lines 306–307).
The swimming centre up the road, and out
there is a big Astro Turf…so I’ll usually go
there, and the other places are sports clubs
and stuff.” (P2, pg7, lines 301–302).
Limited time available to introduce and
explore new activities
Curricular physical education (PE) and
additional non-structured activities such as
walking to and from school and play
during recess.
“Maybe if I’d seen a game or something on
the telly, or one of my mates was going to
somewhere and said that “it’s good”. “You
should come and try it”. I might have a go,
but I probably wouldn’t, because I don’t really
have time…” (P7, pg10, lines 431–440).
“I don’t do any out of school, but in school,
apart from PE I do football at breaks and
dinners.” (P3, pg3, lines 120–121).
Autonomy promoted by independent travel
“I can do it [travel] on my own. It’s like I’m
not dependent on everyone else to do it for
me.” (P7, pg9, lines 361–362).
“It’s either a lift or, because it’s across the
[name of local] field across the road, so I
can just walk over to that…” (P6, pg8, lines
326–327).
Predisposing factors Am I able? Participants attributed poor PA-related
performance to CF related symptoms, such
as breathlessness, fatigue and pain.
CF was not perceived as a barrier to PA
per se.
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Table 1 Illustrative quotes exploring PA perceptions among children and young people with CF (Continued)
“I can do it [PA], but not as good as other
people…I get tired quicker than them, or out
of breath more quicker. I can do it to a certain
point, but then I have to stop.” (P3, pg13,
lines 573–579).
“…there’s nothing really…wrong with me I
can still do it…I’m not stuck like at home or
in hospital. I’m out, like able to do anything,
really.” (P1, pg12, lines 515–525).
For some this results in frustration, anger
and boredom;
“I know just because I’ve got CF doesn’t mean
I can’t do it [PA].” (P3, pg23, lines 1020–1021).
“Well, it’s a bit annoying, because they’re all
doing it, and I’m sat at the side, and it winds
me up that I should be able to do it, but I
just can’t.” (P3, pg13, lines 584–585).
“… I have to do twice as much as my mate,
to do what my mates do, so then when I
can do what my mates are doing I just feel
better, because I know that it doesn’t show
that it’s affecting me, and I can keep up with
my mates and just do all the exercise and
everything.” (P6, pg20, lines 846–849).
CF- related illness can render participants
incapable of engaging in PA.
Perceptions of current well-being
“…Like when I’m ill I feel like I can’t do anything.
I’m sitting on the couch and watching TV, and
I’m not doing much.” (P9, pg23, lines 1004–1005).
“…’cos I am generally quite well, I can do
it.” (P7, pg16, line 702).
“I tend to have quite a high lung function,
and I don’t really get ill a lot…” (P7, pg17,
line 707).
Is it worth it? Some participants reported disliking the
experience of pain, fatigue and breathlessness
associated with PA;
All participants report enjoying PA. Enjoyment
also appears to be inextricably linked to
physical benefits gained through PA
“(I dislike) The way you get tired and out of
breath sometimes.” (P3, pg23, line 1025).
“I like it [PA] because it helps my chest and stuff.”
(P2, pg19, line 864)
“That now and then it gives you the pains
the next day. Like you’re dragging your legs
up the stairs the next day.” (P9, pg35, lines
1517–1518).
Participants also recognise health benefits
associated with PA, both in the short and
long term.
“…it [PA] keeps you active and your lungs
clear, and instead of just sitting in hospital
or something.” (P1, pg14, lines 631–632).
Engaging in PA becomes a normaliser;
“It’s just like you’re doing it because you can,
and you want to. You kind of feel the same
as everyone else for an hour and a half…”
(p7, pg19, lines 803–804).
Reinforcing factors Parental support can generate a negative
affect;
Family support and encouragement
“I did a mile on the treadmill the other day,
and Dad was like, “No, you’re going to do
another one… (I feel like) I’m going to slap
him. Push him off his bike. You do another
mile!” (P7, pg12, lines 493–503).
...my Mum always like, not makes me go,
but if like I’m just too tired, I don’t want to,
she’d be like, “Oh no, come on, let’s get out
or something.” (P1, pg14, lines 641–643).
Peer support
“…my friends who knock on for me, they
are dead nice because they always ask if I’m
ok if I’m out of breath and stuff when I’m
out playing footy and stuff.” (P2, pg21, lines
942–944).
“Like one of us wins a race or wins a game
or something, I can go, “Oh yes, well, I’ve got
CF”, and then it’s like pulling a CF card…I
just find it funny, because they’re like,
“Aaaaaaah! She’s done it again”…we have
a laugh about it….” (P7, pg13–14, lines
565–574).
Significant coaches (conventional and
novel, including PE teachers) influence
“Well, a mixture of everyone. There isn’t really
anyone that influences me any more than
Shelley et al. BMC Pediatrics          (2018) 18:335 Page 6 of 16
Illustrative quotes anchored to the Youth Physical Ac-
tivity Promotion Model [18]. ‘Enabling factors’ allow in-
dividuals to engage in PA, including environmental
factors (access to facilities, weather and safety), levels of
fitness and skill which are impacted by perceived compe-
tence. ‘Predisposing factors’ increase the likelihood of an
individual engaging in PA: ‘Is it worth it? (Benefits and
costs associated with PA) which includes attitudes and
beliefs and interests and enjoyment of PA. ‘Am I able?’
(Perceived competence and self-efficacy). ‘Reinforcing
factors’ reinforce an individual’s PA behaviour (e.g. par-
ents/carers, peers and coaches influence PA behaviour
directly and indirectly).
Phase 2
Participant 3 was hospitalised during the period that
they were asked to wear the ActiGraph, and subse-
quently withdrew from the study. Due to data files being
corrupted, data for P2, P5 and P6 was not available for
analysis. Compliance and mean wear time were generally
good (Table 2).
Phase 3
Participant interviews
Eight interviews were conducted, recorded using a Dicta-
phone and transcribed verbatim. Interviews lasted between
27 min and 75 min (mean = 40.6 min), generating 130 pages
and 324.5 min of audio data (Additional file 9). Transcripts
were deductively and inductively coded, illustrative quotes
were extracted and clustered around emergent themes.
Exploration of participant’s opinions, experiences and
acceptability of the allocated devices resulted in the emer-
gence of a number of themes including wear-ability, de-
vice feedback and compliance.
Wear-ability
Wear-ability of the research-based devices proved to
be problematic for many participants. Participants re-
ported finding the “watch-like” designs easier to wear,
with some participants citing issues with the fitting,
positioning and comfort of the ActiGraph hip-worn
device.
Table 2 Reporting participant characteristics, compliance and wear time from GENEActiv and ActiGraph accelerometers
P Age Group (Years) Gender Allocated device(s) Compliance (Days worn) Valid days included (≥10 h·day) Mean wear time (h)
1 ≤10 Female ActiGraph & Pedometer 6 4 12.5
2 > 10 Male ActiGraph & Fitbit
3 > 10 Male ActiGraph & Pedometer
4 > 10 Male GENEActiv 7 6 16.3
5 ≤10 Female ActiGraph & Pedometer
6 > 10 Male GENEActiv & Smartphone
7 > 10 Female GENEActiv 6 6 13.3
8 ≤10 Male GENEActiv & Fitbit 7 4 23.3
9 > 10 Female GENEActiv & Fitbit 7 6 14.8
The data presented are from the research devices which are able to provide objective data. A self-report questionnaire was used to assess compliance of the
consumer level devices and acceptability, which is further explored in Phase 3
Table 1 Illustrative quotes exploring PA perceptions among children and young people with CF (Continued)
someone else… Family, people in the CF
team, my PE teachers.” (P4, pg11, lines
498–503).
The CF specialist physiotherapist was
identified by participants (P2, 3 and 9) as
the CF clinician who most encourages
them to be physically active. Participants
also perceive health-related information
and advice to be trustworthy and reliable;
“I think that it’s good advice, and that I
should take it.” (P1, pg11, line 482).
Family facilitating activity (e.g. driving to
sports clubs or engaging in family
activities)
“My Mum or Dad would usually take me.”
(P4, pg7, line 279).
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“The Fitbit was basically just like wearing a watch,
but the ActiGraph kept getting in the way of when I’d
be doing my PE and stuff” (P2, pg4, lines 145–146).
“Well, I liked wearing the wrist one because I just liked
it more than the other [ActiGraph]…it didn’t have
anything for me to do on it, but it kept falling down at
my waist and then making my waist really itchy and
stuff.” (P2, pg1, lines 36–45).
“because, do you know when you put it on the side, it
hurts…it did hurt when I was doing some jogging” (P5,
pg2–3, lines 62–70).
Participants trialling the GENEActiv commented on
the thickness of the wrist strap, some finding it inter-
fered with activities
“It was just a bit thick, and it got in my way of doing
general activities I do every day, and I had to be
careful that I didn’t knock it and stuff like that, and it
was quite thick. People noticed it a lot more, and was
asking me about it, thinking it was a watch, and then
when they actually saw it there was no watch… I was
just a bit like, oh...” (P9, pg1, lines 27–30).
whilst others found it didn’t interfere with activities.
“it didn’t get in the way of me doing anything, or
didn’t prevent me from doing anything either…” (P4,
pg1, lines 35–36).
The visual appearance of the devices often attracted
attention from others. This was not perceived to be an
issue by some participants, though for some older par-
ticipants this attention was unwanted, with one opting
to tell inquisitive others that the device was a broken
watch.
“They just asked what it was and what it did,
and someone asked what the time was with the
GENEActiv, and I had to say, “Oh no, it’s not a
watch, it’s a blah, blah, blah…” (P7, pg4, lines
180–182).
“They’d just ask for the time and I’d get my phone out,
and they’d be like, “Why didn’t you just use your
watch?” I’d be like, “because it’s this monitoring thing
for the hospital”, or like my Mum said, “It’s broke.”
(P6, pg5, lines 142–144).
The consumer level Fitbit with a smaller rubber strap
was perceived to be more comfortable than the
research-based device and proved favourable.
“It was a lot more comfortable, the Fitbit. It looks
‘slicker’, it looks smarter than a big bulky thing.”
(P8, pg2, lines 74–75).
P6 did not encounter any problems having their
smartphone on their person whilst engaging in PA.
“Well I usually carry my phone everywhere anyway, so
it didn’t really affect me.” (P6, pg12, line 382).
Device feedback
The LED display of the consumer devices was reported
as a desirable feature, with participants enjoying the
interactive nature of these devices.
“It was fun to know that I could look back and see
how much I was doing…how many calories I’ve
burned, how many steps I took, which was good.” (P4,
pg1, lines 25–31).
The information provided by these devices also facili-
tated self-monitoring for some participants assuring
them they had achieved adequate levels of PA.
“I suppose it taught me that what I was doing, I was
doing it right. Like playing table tennis, I was actually
doing the right amount of activity that I should be”
(P4, pg13, lines 566–567).
Other participants found the level of information avail-
able and interactive dashboard to be overwhelming and
complicated, with some opting not to use it at all.
“It was a bit confusing with too much going on, so it
was hard to use.” (P7, pg13, line 581).
P6 reported that the smartphone based application
provided sufficient PA-related information and was sim-
ple to use.
“I didn’t really dislike anything, because it was so
simple, and showed you what you wanted to see.” (P6,
pg12, lines 376–377).
The research-based devices do not provide partici-
pants with PA-related information or feature a display.
Compliance
Some compliance issues were highlighted when discuss-
ing results derived from the accelerometry data. Explor-
ation of whether participants remembered to wear their
devices or used any strategies to do so revealed that
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wearing the devices became integrated into their daily
routines.
“I just think it feels like a natural thing, like say you’re
getting ready for school in a morning, it’s like you get
your t-shirt on, and you put it on basically, like
natural.” (P1, pg4, lines 107–108).
Leaving their device close to where they slept acted as
an adequate prompt for participants.
“Well, I kept it next to where I sleep, so as soon as I
woke up I’d put it on.” (P4, pg3, line 132).
Although, one participant found that despite leaving it
by their bedside, they forgot to wear their GENEActiv
device.
“I didn’t forget with the Fitbit, but I could just keep it
on all the time…I think I forgot with the GENEActiv
because you have to take it off at night, so I might
forget to put it on in the morning.” (P7, pg4, lines
148–151).
Participants opted to remove the devices during activ-
ities due to concerns about damaging the devices and/or
causing injury to others.
“Well, usually when we go on the field, we always just
run after each other, like taking each other out…but I
wouldn’t go too mad on doing that compared to what
I normally do… If I take someone down, I won’t just
damage whatever it is.” (P2, pg6, lines 255–258).
“so you actually might hurt someone else, and you
might hurt yourself in gymnastics” (P7, pg4, lines
140–141).
Summary
Overall, participants reported that they enjoyed testing
the devices, stating a preference for wrist-worn devices
and devices that allowed interaction and feedback. Com-
pliance was generally good, suggesting that the devices
were not a significant burden, although P5 did not pro-
vide sufficient wear time.
Health care professional interviews
Three interviews were conducted, recorded using a Dic-
taphone and transcribed verbatim. Interviews lasted be-
tween 46 min and 55 min (mean = 51.3 min), generating
38 pages and 154 min of audio data. Transcripts were
deductively and inductively coded, illustrative quotes
were extracted and clustered around emergent themes.
The online Physiotherapist survey had 30 respondents,
93% (n = 28) of respondents agreed that PA monitoring
devices could influence their clinical practice. Qualitative
data provided are consolidated and discussed with data
obtained from the HCP interviews.
Exploration of HCP’s opinions, experiences and ac-
ceptability of the PA devices for PA monitoring also re-
sulted in the emergence of a number of themes
including, perceived benefits, perceived barriers, and pa-
tient and families’ acceptability.
Existing knowledge
None of the HCP’s had previously used PA monitoring
as part of their clinical practice. HCP-C and HCP-P re-
ported using consumer devices and applications to as-
sess their personal PA levels, though HCP-P did
acknowledge concerns about the validity of these
devices.
PA is not formally measured as part of routine clinical
practice, however an exercise test is administered as part
of a patient’s annual review. Whilst the exercise test of-
fers clinically relevant and prognostic information, it
does not provide information about daily PA, which was
perceived to be a limitation.
“…the once a year test will prove what they do on that
day, and it doesn’t tell us how they do their normal
week, cope on a day-to-day week, so we don’t have
any kind of measure about what they do, other than
subjective, them telling us, “I do, and I’m fine”. You
don’t have that information, so I suppose this just gives
you over a period of time, if it’s a week or whatever, or
two weeks if they were an in-patient, it would give us
kind of better understanding of how they’re functioning
on a day-to-day level.” (HCP-P, pg11, lines 411–416).
PA was reported to be informally discussed on an indi-
vidual basis and advice may be given accordingly al-
though this is not standardised.
“I will ask them what they do, what sports they do,
and how active they are, particularly if we’re having
problems with weight gain or weight loss, so say for
example you have somebody present to you who’s
maybe lost a significant amount of weight, so part of
that discussion will be about are you doing more
activity, have you joined any other groups, are you
doing more planned activity, trying to look at reasons
why they might have lost weight. We don’t formally
measure how much activity they’ve done and what the
energy cost of that is…” (HCP-D, pg4, lines 128–140).
This reveals that, for these practitioners, current as-
sessments are not sufficient in providing information
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about habitual PA, therefore individualised interventions
to promote PA are limited to informal discussions and
generic PA advice.
Perceived benefits
Although experience of using PA measurement devices
in clinical practice was limited, there was consensus
among HCP’s that PA monitoring devices offered a
number of potential benefits.
It was perceived that PA monitoring could provide an
‘objective’ measure of PA, which would allow HCP’s and
patients to track PA alongside markers of health over a
given period.
“I think, I suppose, trying to help young people to see
that actually being physically inactive is potentially
having an impact on their health and on their
respiratory function, and helping them to see that if
they can just increase their activity a bit, then that
might have a positive impact on their respiratory
health.” (HCP-D, pg5, lines 185–188).
Objective PA measurement is often used to inform de-
velopment and evaluation of interventions to promote
PA [25, 26] and was highlighted by HCP-C as missing
from current practice.
“…I think we need a more consistent approach across
the team, so it will help that. We can formalise more
of our interventions with the patients, but we don’t
know what those interventions should be, but we can
be a bit more robust about it, a bit more sort of
systematic, as opposed to just making it up as we go
along, which is kind of what we do at the moment.”
(HCP-C, pg9, lines 312–315).
The potential for using the devices as an intervention
in themselves was also acknowledged particularly in re-
spect of a motivational aid.
“I think it would be maybe even a realism about what
they do, or how little they do, or it reassures them that
they’re doing enough, if they’re doing a lot. Certainly
from our experience of monitoring when they do their
nebulisers, they have been very very, surprised when
they know what they’ve done, compared to what they
think they’ve done. So I think that the effect might be,
“Oh my God, I thought I was doing lots more than
that”, or it might motivate them to do better, to
improve.” (HCP-P, pg8, lines 293–298).
HCP-C concedes that informing a patient of their low
PA may have a detrimental effect, rather than encourage
PA.
“…the ones we need to target are the ones who hate
physical activity, who find gymnasiums an
abomination. And we have a significant number of
patients like that, and also quite a large proportion of
our young women who are fourteen, fifteen, sixteen,
exercise seems to be a non-cool thing for young girls par-
ticularly, to do. So those are the challenges we face. Now
I’ve absolutely no hesitation to feel that our well-
motivated patients will completely embrace this and
will love it, and will get a lot out of it, and actu-
ally use it in their lives, and that’ll be great for
them. But I have extreme anxieties how [sedentary
patients] will not in any way be helped by this kind
of monitoring. I don’t know. That might not be true.
I don’t know what the answer is. If you monitor
somebody and show them that the level of activity
they’re doing is woeful, then that may motivate
them to take a step forward themselves, and try
and sort it out. I suspect not, but I don’t know.”
(HCP-C, pg5, lines 151–161).
Acceptability
Owing to the perceived benefits of the devices, there
was strong acceptability amongst the HCP’s that devices
could become part of their routine care, progressing the
service and moving with innovation.
“we could very easily fit it into what we do. We
have a very good relationship with our families, a
respectful relationship, and we have the capacity
within our care programme to sort of slot it in. We
have plenty of time. We see them regularly in clinic
every two to three months. We do annual review,
obviously every year, and we see them in between
times. Our families are very engaged, they’re very
empowered, they want to do things for the better,
on the whole, and they’re very keen to take on, to
embrace new developments and new technologies.”
(HCP-C, pg4, lines 132–137).
It was reported that use of the devices would be
the responsibility of the CF Physiotherapist, (HCP-P,
pg10, lines 386–390) and although some scepticism
was anticipated from more established members of
the CF team, it was felt that the importance of PA
would supersede any resistance to the acceptability of
the devices.
“I think generally everyone can appreciate the
importance of exercise, but there is some definite
variability amongst the team as to how we do that,
and how important people feel it is.” (HCP-C, pg11,
lines 394–396).
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Aside from the acceptability among HCP’s, the import-
ance of working in partnership with patient families was
highlighted.
“I think we would really need to have families on
board in partnership, and it would be something that
they would need to see as a routine part of their CF
care rather than just something that is a bit different
and a bit special.” (HCP-C, pg4, lines 116–119).
Nevertheless, HCP-C felt that patients and families
would embrace the integration of technology-based
strategies to improve the management of CF, as demon-
strated by the acceptance of other medical device such
as the I-neb.
“Well, I think that the relationship you have with your
team, your CF team, is a very close relationship. It’s
not always a relationship based on the greatest
amount of honesty, and in those cases it’s just a bit
tricky, but we’ve kind of dealt with a lot of these issues
with a lot of our aerosol delivery devices, and are now
able to incorporate data logging, so we have dealt with
these issues with the i-neb, and we’ve been able to sort
of sit down with the families and the young person in
a very open way, and say...‘Just looking over the course
of three months, we’ve seen you’ve gone from being a
hundred per cent adherent to what you’re doing, to
sort of just doing it once a day or whatever, and they’re
going, “Yes, it’s a real struggle. Maybe we could go
down to once a day”. So working in that open way has
worked, I think, and we’ve been able to do some really
good stuff in improving adherence in our patients with
CF, and support them with treatments that they might
be finding difficult or impossible.’” (HCP-C, pg10, lines
356–374).
In order to maintain standards of patient care a num-
ber of considerations were suggested as needing to be
addressed prior to the implementation of PA monitoring
devices including; cost-effectiveness, available resources,
staffing, cross-contamination and accuracy of the
devices.
“I think handling data is the key thing, and making
sure that the data is readily available in a way that’s
readily understood, both professionals and the family.”
(HCP-D, pg11, lines 413–414).
“I think we need to know what monitors and which
are the best…We need to decide what information we
need from them as to what benefit they’re going to be.
So I think that’s one of the key issues, and I think they
also need to be relatively affordable…And cleanable,
and from that aspect, so that they can be wiped
down.” (HCP-P, pg11, lines 394–398).
Summary
HCP’s acknowledged that overall their current practice
does not include adequate measurement of PA or suffi-
cient interventions to promote PA engagement. HCP’s
recognised the potential benefits that PA monitoring de-
vices could have in clinical monitoring, informing inter-
ventions and motivating patients on an individual basis.
Acceptability among the CF team was good, with the
Physiotherapist deemed as the individual most likely to
be responsible for using the devices. A number of poten-
tial barriers will require consideration prior to use as
part of routine care.
Phase 4
Priority issues emerging from the focus group were orga-
nised into three themes, patient-related issues, clinical
practice issues and research issues as outlined in Table 3.
Patient-related issues
The theme of a ‘lifestyle based approach to PA’
centred on parental influences on PA through their
reinforcement and facilitating of PA to promote PA en-
gagement as a ‘part of normal life’. This was viewed by the
expert members as an important patient-related issue,
which should form part of any recommendations and may
warrant further research, for example HCP-P noted;
“Really important is to continue ongoing education on the
exercise with the patients and the families, throughout all
ages and stages of disease progression, with discussion
concerning expectations of the patient, the family and the
therapist, and to reinforce that exercise and activity as a
lifestyle choice rather than prescription, in order to
improve compliance.” (P3, pg3, lines 92–96).
The ‘motivation is a key issue’ theme included issues
relating to the use of goal setting to promote PA and the
impact that device feedback may have on motivation, ei-
ther positively or negatively.
“You might get that instant feedback, but you don’t
know how to interpret that information correctly.
That could have a negative impact on your
motivation, or a positive impact, or no impact.”
(P4, pg18, lines 691–693).
Clinical practice issues
‘Education (for practitioners, parents/carers and chil-
dren and young people)’ was identified as a key
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clinical practice issue and included education around
physical activity monitoring and promotion. It was
also suggested that this education could encompass
an element of counselling.
“In terms of the education, I think that kind of
counselling, it doesn’t have to be a psychologist. It can
be, that type of support can be offered in different
ways through different roles, through training, through
educating parents. It’s not necessarily about
parachuting a specific practitioner in. I guess it’s
looking for that opportunity, capacity, and the
willingness to sort of take on board some of that, in the
same way that exercise professionals who work in
gyms, they’re not exercise psychologists, but they are
very much at the front end of applying principles of
exercise psychology in order to make sure that the
people they address, whether it’s the cardiac rehab
plan or reducing obesity, whatever it is, they’re
sort of applying the technique.” (P2, pg19, lines
698–706).
It was also viewed as important that both clinicians and
patients are able to view and interpret the feedback ob-
tained from the devices. This will have implications for
the choice of device used and the balance between re-
search data and feedback from consumer devices.
Research issues
A priority research issue that emerged was ‘Cost’, with
members of the focus group stating that funding would
Table 3 Displaying ranking of priority issues identified during phase 4
Individual priority ranking Sum
total
Collective
rankingHCP-C
(P5)
HCP-P
(P3)
Researcher
1 (P4)
Researcher
2 (P2)
Part 1: Patient-Related Issues
1 Lifestyle based approach to physical activity 5th 1st 2nd 1st 9 1st
5 Motivation is a key issue 2nd 2nd 1st 6th 11 2nd
6 Perceived importance of physical activity and the data retrieved by the devices 4th 5th 3rd 3rd 15 3rd
3 Experience of CF symptoms during physical activity 6th 3rd 4th 4th 17 4th
7 Importance of fitness over physical activity 3rd 7th 5th 2nd 17 5th
2 Decline of Physical activity 1st 4th 7th 8th 20 6th
4 Importance of clinical versus “field” testing of physical activity levels 7th 8th 6th 5th 26 7th
8 Structured vs. non-structured activity 8th 6th 8th 7th 29 8th
Part 2: Clinical Practice Issues
2 Education (for practitioners, parents/carers and children and young people) 1st 1st 7th 2nd 11 1st
4 Importance of meaningful feedback 5th 5th 3rd 3rd 16 2nd
1 Role of feedback provided by devices 4th 6th 2nd 5th 17 3rd
9 Clinical barriers identified (cost, resources, time) 10th 2nd 4th 1st 17 4th
8 Issues of compliance raised 3rd 4th 5th 7th 19 5th
6 Sustainability of the physical activity engendered by the tool used in terms of: 2nd 7th 9th 6th 24 6th
7 Importance of accruing 7 days worth of physical activity data: 7th 8th 6th 4th 25 7th
10 Team message is important 6th 3rd 8th 8th 25 8th
3 Testing vs. Monitoring 8th 9th 1st 9th 27 9th
5 Distinction between the use of physical activity monitoring devices as a research
tool vs. commercial tool
9th 10th 10th 10th 39 10th
Part 3: Research Issues
1 Cost 5th 1st 1st 1st 8 1st
4 Children and young people involvement required to inform the research process 1st 2nd 3rd 4th 10 2nd
3 Type of data produced by research vs. commercial devices 2nd 3rd 2nd 5th 12 3rd
5 Literacy and understanding 3rd 4th 5th 3rd 15 4th
2 Issues of compliance 4th N/A 4th 2nd N/A N/A
Expert members of the phase 4 focus group were asked to rank the issues discussed during the focus group meeting in order of priority
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be required to support further research in the area and
the clinical use of PA monitoring devices.
“We need some funding to be able to do this.” (P2,
pg23, line 855).
‘Children and young people involvement required to
inform the research processes’ emerged as a recommen-
dation from the focus group discussion.
“…they are very articulate and able to talk about
these devices, and therefore in any future research
we should make sure that it’s not just research on
children, it’s research with, and alongside, and involve
them in the design.” (P2, pg24, lines 896–898).
Summary
The focus group discussion, emergent themes and pri-
oritisation of key issues were consolidated into a number
of agreed recommendations and areas for consideration
concerning the application of PA monitoring in clinical
practice.
Recommendations from phase 4
Interventions to promote PA engagement in children
and young people with CF should be individualised and
involve family members to promote PA as part of an ac-
tive lifestyle, as opposed to that referred to as prescribed
exercise.
Patients should receive education and support along-
side the PA data obtained from monitoring devices.
The process of developing interventions and their sub-
sequent evaluations should involve patients and their
families throughout the research process who, from the
outcomes of this study, are well informed and able to
contribute to such matters effectively.
Future research considerations
Consideration should be given to the impact that device
feedback may have on motivation. It is acknowledged
that patients and their parents/carers may respond to
device feedback on an individual basis with some having
a negative response.
The choice of device will influence a number of key is-
sues identified including, motivation, meaningful feed-
back, cost and clinical application.
Discussion
Phase 1
We employed a socio-ecological model (YPAPM) [17] to
facilitate a theory-driven, comprehensive approach to
understanding the perceived enablers and barriers
among this cohort. Collectively, findings indicate that
children and young people with CF engage in a variety
of physical activities comparable to their non-CF peers.
CF was not perceived as a barrier per se, although re-
duced exercise capacity and exercise related symptoms
were reported to have a detrimental impact on PA en-
gagement, as previously reported in children and young
people with CF [27]. As in previous research, there was
no evidence of PA avoidance as a result of CF related
symptoms in the current study [19]. Rather, PA engage-
ment offered an opportunity to ‘normalise’ their condi-
tion by attaining PA levels similar to their non-CF peers.
Whilst social comparison in this way can encourage PA
engagement it can also be detrimental to PA engagement
depending on the level of self-monitoring and percep-
tion of differences/similarities in PA ability [17].
Key facilitators of PA engagement were health and
improved fitness. Key reinforcing factors were the in-
fluence of parents/carers, peers and HCPs who influ-
ence PA directly and indirectly. Direct influences
include facilitating engagement through pursuing ac-
tivities together, transport to activities or encourage-
ment [17]. Indirect influences may include affecting
predisposing factors, such as attitudes and beliefs (Is
it worth it?) or perceived confidence and self-efficacy
(Am I able?) [17]. Individuals who report positive PA
experiences also report receiving family support and
encouragement [14].
Phase 2 and phase 3
Findings suggest that children and young people with CF
are mostly compliant with wearing a range of PA monitor-
ing devices, which is further explored in phase 3.
When determining the feasibility of using PA monitors
in clinical practice, guidelines set by Bowen et al. [28]
were utilised, the primary areas of evaluation were ac-
ceptability, implementation, practicality and integration.
Qualitative data supported the acceptability of PA moni-
toring devices among both patients and clinicians. A
number of issues relating to the visual appearance and
comfort of some of the devices were identified, with
better acceptability reported for wrist-worn devices.
Qualitative data obtained from HCPs suggests that im-
plementation of PA monitoring into routine clinical care
may be feasible. The data collected from the current
study suggests that PA monitoring in clinical care may
be limited by practicality. The number of devices which
did not provide data due to technical faults was high (4
out of 9), which may limit the feasibility of using these
device in clinical practice. However, accelerometers are
widely used in clinical research and typically device fail-
ure is much lower than reported in the current study
[29]. Data from the five devices which did not experi-
ence any malfunctions provided usable PA data,
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demonstrating good participant compliance, as indicated
by valid wear time. Demand was not specifically assessed
as PA monitoring formed part of a wider researcher
study, therefore it was not possible to determine if pa-
tients’ decision to not take part was a result of PA moni-
toring specifically or the study more broadly. Of the 13
participants screened only 9 (70%) were willing to par-
ticipate, which may suggest moderate demand.
From the follow-up interviews three themes were
identified; wear-ability, device feedback and compliance.
The visual appearance and comfort of the devices was
perceived as important, with wrist-worn devices reported
to be more favourable. A combination of these factors
may contribute to improving compliance to wrist-worn
devices [24, 30]. Feedback from devices was also pre-
ferred, as it allowed self-monitoring and provided motiv-
ation. Monitoring devices may have a role in clinical
practice as a motivation tool, and though there remains
a lack of evidence to support clinical use [31], accept-
ability of the devices was high among HCPs who felt
that devices have the potential to provide clinically rele-
vant information which could improve current practice.
The data from the current study does not allow compar-
isons to be made between the acceptability of the con-
sumer level devices and the research grade devices,
though only the research grade devices are supported by
evidence of reliability and validity [16]. The CF Physio-
therapist was identified as best placed to implement the
use of PA monitoring devices, although the wider CF
team also have a role in promoting PA and supporting
monitoring. In addition to Physiotherapists, CF centres
are increasingly employing members of staff specifically
to deliver exercise testing and prescription [32, 33] and
may have additional interest and/or qualifications in
exercise-related fields, making them well placed to utilise
PA monitoring in the clinical setting.
Phase 4
Patient related priority issues included a lifestyle-based
approach to increase PA and the importance of motiv-
ation and family involvement. Clinical priorities included
education alongside PA monitoring (for clinicians, pa-
tients and parents/carers), and the requirement for
meaningful feedback. A wrist-worn device capable of
providing research level data, which can be interpreted
and analysed by clinicians, whilst also featuring a display
for time or user feedback if desired would appear to be
acceptable amongst both patients and clinicians (e.g. the
ActiGraph GT9X Link, although there are a number of
devices available).
The cost of using monitoring devices in clinical practice
was also identified as a priority issue. Consumer level de-
vices may offer a lower cost alternative to research based
devices and may be perceived to be more ‘stylish’ and less
obtrusive. Although beyond the scope of the current
paper, the clinimetric properties (reliability, validity and
responsiveness) of research grade devices has been
reviewed elsewhere [16], providing evidence for their use.
Consumer level technology is constantly improving, and a
number of devices have become commercially available
since this research was conducted which may offer validity
comparable to research grade devices, with further im-
provements anticipated in future [34]. Though agreement
with research grade devices is good, validity of consumer
devices remains highly variable, which may cause concern
for clinical use [34]. A third party software package ‘Fita-
base’ (Small Steps Labs LLC, San Diego, CA) has recently
become available, which allows Fitbit data to be analysed
in a similar manor to the research devices. The choice of
device may ultimately be determined by the requirement
for user feedback and whilst user feedback is avoided in
observational research to control for the risk of participant
reactivity, it may be appealing for PA interventions as
users can view a range of variables (steps, activity, energy
expenditure etc.) [34]. However, HCPs expressed concern
that device feedback may be demotivating in some chil-
dren and young people with CF, suggesting feedback
would be best given as part of a package of care delivered
from with the CF team, which also included education
and support.
Limitations
A number of limitations are present in the study. Whilst
there is a small sample collected form a single centre,
the study design allowed for the collection of in depth
qualitative data taking a broad perspective with repre-
sentatives of patients and clinicians. Participants were
active and well at the time of recruitment and the
self-selecting nature of recruitment perhaps resulted in a
sample of patients already motivated to be physically ac-
tive. It is not known if similar findings would be seen in
patients with more severe disease or at the time of an
exacerbation. However, HCPs are experienced working
with a variety of patients through periods of fluctuating
health, which will have informed their responses during
the interviews and prioritisation of key issues. Not all
participants approached agreed to partake in the study
and we did not explore their reasons for refusal. A num-
ber of technical malfunctions occurred with the PA
monitoring devices, although this is a risk associated
with monitoring PA in free-living, the number of issues
in the present study was greater than anticipated.
Conclusions
PA monitoring devices appear to be an acceptable method
for the objective assessment of PA among children and
young people with CF and their clinical team, though fur-
ther research is required to determine the validity and
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reliability of consumer level devices. Wrist-worn devices
that are unobtrusive and can display feedback are most ac-
ceptable for patients and clinicians.
Experiences of PA among children and young people
with CF are largely comparable to their non-CF peers,
with individuals engaging in a variety of activities. CF
was not perceived as a barrier per se, although partici-
pants acknowledged that they could be limited by their
symptoms.
HCPs perceive monitoring devices to be a beneficial
addition to routine clinical care, although education for
clinicians, patients and families is required. Health pro-
fessionals expressed enthusiasm for PA monitoring, but
caution that the information is processed in a positive
manner in partnership with the young people.
Future considerations
This study highlights that whilst PA monitoring has po-
tential as a clinical tool, future work is required to de-
velop a programme of education and support to allow
clinicians to utilise the devices, followed by support for
patients and families with the aim to understand and use
the data obtained for the devices to promote PA engage-
ment as part of an active lifestyle.
A variety of PA monitoring devices are widely available,
with each offering a range of different features. Careful
consideration should be given to the purpose of monitor-
ing PA in order to select an appropriate device. A device
which can be bespoke for individual patients is required to
control the use of feedback as a motivational tool to allow
for self-monitoring whilst avoiding negative impact.
Further exploration of perceptions of PA throughout
childhood and adolescents will improve understanding
of how children and young people with CF conceptualise
PA. By understanding the factors impacting on PA, CF
health care professionals will be better placed to support
patients and improve health outcomes. Further research
exploring children and young people’s perceptions of PA
monitoring devices being used as part of routine CF care
may also be warranted.
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